Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Premier Inc. says business is booming thanks to the Affordable Care Act and newly passed legislation reforming the Medicare provider payment process.
The North Carolina-based group purchasing organization said that both pieces of legislation are pushing providers away from fee-for-service payment models and toward value-based healthcare. Those systems, which rely on bundled payments based on performance, are pushing healthcare providers to sign on to the health management strategies Premier offers, the company said. Read more
Corindus Vascular Robotics last week said it hopes to raise as much as $46 million and uplist its stock to a larger exchange as it looks for another indication for its CorPath robot-assisted surgery platform.
Waltham, Mass.-based Corindus said it hopes to list on the New York Stock Exchange under its current “CVRS” symbol. Read more
The FDA granted pre-market approval a few months ahead of schedule to the Senza chronic pain device made by Nevro Corp., allowing the company to label the device as superior to conventional spinal cord stimulators.
The safety watchdog said it approved Senza “as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain and leg pain.” The Senza device is designed to deliver up to 10,000Hz to the spinal cord, allowing it to avoid the tingling sensation known as paresthesia that bothers some patients. Read more